Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

    Cancer Categories
    • Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung,Skin
    Karmanos Trial ID
    • 2022-030
    NCT ID
    • NCT05103358
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator


    Primary Objectives:

    • To determine clinical benefit as described by the overall response rate (ORR) of nab-sirolimus via independent radiographic review (IRR) in patients with malignant solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes

    Secondary Objectives:

    • To evaluate the duration of response (DOR), disease control rate (DCR), time to response (TTR), and progression-free survival (PFS) via IRR, and overall survival (OS) of nab-sirolimus
    • To evaluate changes in Quality-of-Life
    • To describe the safety and tolerability of nab-sirolimus
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266